Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus for idiopathic inflammatory myopathy
ChiCTR1900028143Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jan 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tacrolimus in dermatomyositis (DM), polymyositis (PM) and Autoimmune Myopathies (3 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Myositis Disease Activity Assessment Tool. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
tacrolimus
03
Conditions
dermatomyositis (DM)polymyositis (PM)Autoimmune Myopathies
Beyond the preview
Go deeper on ChiCTR1900028143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028143.